Occult adenocarcinoma of the pancreas in a 17-year-old patient with immunosuppressed leukemia.
D000230:Adenocarcinoma / Q000139:chemically induced / Q000150:complications* / Q000276:immunology; D000293:Adolescent; D000367:Age Factors; D001344:Autopsy; D001932:Brain Neoplasms / Q000532:radiotherapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007945:Leukemia, Lymphoid / Q000150:complications* / Q000532:radiotherapy; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009378:Neoplasms, Multiple Primary / Q000139:chemically induced*; D010179:Pancreas / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000150:complications* / Q000276:immunology; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate